Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
'Approximately half of the world's population live in areas with a risk for dengue, making it a serious public health threat,' said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, global clinical development, Merck Research Laboratories. 'The initiation of the MOBILIZE-1 study, the first Phase 3 trial in our clinical development program, marks a key milestone in our work to help address this widespread mosquito-borne disease. If successful, V181 could provide an important single-dose option for at risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe.'
Merck is committed to research and innovation that aims to help protect the millions of people at risk for dengue virus infection and is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is a significant health threat.
About MOBILIZE-1 (NCT07013487)
MOBILIZE-1, also known as V181-005, is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, immunogenicity and efficacy of V181, an investigational vaccine for the prevention of dengue disease. The study aims to enroll approximately 12,000 healthy individuals 2 to 17 years of age who will be randomized to receive either a single dose of V181 or placebo. The study is planned to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific region, including Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. The primary endpoints of the study are safety and efficacy of a single dose of V181 in preventing symptomatic virologically confirmed dengue (VCD) of any severity, due to any of the four dengue serotypes, regardless of prior dengue exposure. The key secondary efficacy endpoint is evaluating a single dose of V181 in preventing symptomatic VCD of any severity due to each of the four dengue serotypes, regardless of prior dengue exposure. Additional secondary endpoints include evaluating a single dose of V181 in preventing symptomatic VCD with warning signs, severe VCD and hospitalization.
For more information on the trial, visit clinicaltrials.gov.
About V181
V181 is a live attenuated quadrivalent vaccine currently being investigated for the prevention of dengue disease caused by any of the four dengue virus types (DENV-1, DENV-2, DENV-3, and DENV-4). V181 is designed to be a single-dose vaccination and is being studied in individuals to provide protection against dengue, including severe forms, whether the individuals have been previously infected with the dengue virus or had no prior infections.
About Dengue disease
Dengue disease is one of the fastest growing mosquito-borne diseases that affects not just the health but often the economic stability of communities across the globe. It is a rapidly emerging cause of serious and sometimes debilitating illness in tropical and subtropical countries. With approximately half of the world's population, or four billion people, at risk for dengue disease, it represents a critical public health challenge. Globally, around 105 million dengue viral infections occur annually, with approximately 50-60 million being symptomatic on average per year. While the majority of infections are uncomplicated, serious illness caused by dengue can be severe and lead to death (on average, ~4-11 million cases result in hospitalizations per year and there is an average annual incidence of ~29,000 dengue-related deaths worldwide). Symptoms of mild dengue fever may include a high fever, a rash and muscle and joint pain. Dengue fever might evolve to severe dengue, formerly known as dengue hemorrhagic fever, which can cause severe bleeding, a sudden drop in blood pressure, and in rare cases, death.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Lilly first to opt for confidential reimbursement price in Germany
Eli Lilly has announced that it will take up the option of a confidential discount in Germany for Mounjaro in Type 2 diabetes (T2D). The announcement has reignited controversies around the disputed policy, and the alleged link between its implementation and Lilly's large new investment in Germany, announced in 2024. Eli Lilly (US) has confirmed that it intends to take up the option of a confidential reimbursement price for its dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Mounjaro (tirzepatide) in the treatment of T2D in Germany. This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act (Medizinforschungsgesetz, MFG). Lilly's plan to opt for confidential pricing was first reported by German newspaper Süddeutsche Zeitung and the public broadcasters Norddeutscher Rundfunk and Westdeutsche Rundfunk, which referred to a communication from the company to physicians in Germany, explaining its plans and reportedly asserting that the price negotiated with the statutory health insurance (Gesetzliche Krankenversicherung, GKV) funds would be favourable for the GKV system. The introduction of the option of confidential reimbursement prices has been highly controversial, with GKV funds particularly concerned that it would lead to a surge in reimbursement spending. It has also been controversial because of Germany's established position as a champion of price transparency: Germany stands more or less alone as a European country in which discounted reimbursement prices of new originator therapies can be publicly accessed, and it has, until now, held out against attempts to introduce confidential pricing. It should be emphasised here that the situation is different in the case of off-patent medicines, which are predominantly subject to discount contracts between manufacturers and GKV funds, details of which are strictly confidential. Such was the controversy around the proposal to introduce confidential pricing that in the final version of the MFG, thanks mainly to the lobbying of the GKV funds, the confidential pricing option was made so unattractive that the main pharmaceutical industry associations predicted vanishingly small interest in taking it up. The imposition of an additional 9% discount — on top of the negotiated discount — and the requirement to pay back overcharged trade surcharges and sales tax (when paying back the difference between the realised price and the publicly available higher price) made it economically unappealing. And until now, not one single company has requested a confidential reimbursement price. The German Association of Research-Based Pharmaceutical Companies (Verband Forschender Arzneimittelhersteller, VFA) confirmed in an 11 July 2025 press release that no single company had opted for a confidential reimbursement price during the first half of 2025. The controversy does not end there. Soon after the proposal for confidential pricing was put forward as part of the early iterations of the MFG, in an article published by RedaktionsNetzwerk Deutschland (RND) — the joint corporate newsroom of the German Madsack Media Group — it was claimed that the inclusion of confidential pricing in the MFG was directly related to Eli Lilly's decision to build a large new production facility in Alzey, in Germany's Rhineland-Palatinate federal state. It was suggested that Lilly stood to gain in particular from having the option of a confidential reimbursement price, given that Mounjaro is approved both for T2D and obesity, and if the considerably lower price resulting from negotiations between the company and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) for the T2D indication were to be made publicly available, it would be difficult to maintain a significantly higher price for the obesity indication. In Germany, as in most other European countries, obesity therapies do not, as a rule, benefit from reimbursement. In a later report in Süddeutsche Zeitung, it was claimed that internal government documents had been made available showing that the confidential pricing measure was included in the MFG as a condition for the decision to build the factory. The allegations were dismissed by Lilly and former health minister Karl Lauterbach, although in the meantime, the MFG has been given the widely quoted sobriquet 'Lex Lilly.' Price negotiations between the GKV-Spitzenverband and the company for Mounjaro in T2D have already been concluded, according to the news website of the television news program Tagesschau, although at this stage, there is no official notification of a reimbursement price on the GKV-Spitzenverband website. Predictably, the news of Lilly taking up the option of a confidential reimbursement price for Mounjaro has prompted numerous sensationalist reports in German media, in which Lilly is presented as having used its influence to bring confidential pricing into effect. Tabloid newspaper Bild and popular news weekly Focus both ran articles presenting this view, both also presenting the view that ordinary people paying GKV contributions would have to pick up large additional costs, thanks to the law change. However, the reality is that price transparency remains the rule in Germany, and this is a very isolated exception. And there are unlikely to be many repeats. "Lilly first to opt for confidential reimbursement price in Germany" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 injectable therapies, Zepbound and Wegovy, leading the field. Although Zepbound entered the market after Wegovy, it has achieved rapid sales growth, fueled by strong demand. LLY had been enjoying a significant edge over Novo Nordisk, after Zepbound outperformed Wegovy in weight-loss efficacy in a head-to-head clinical study. In the first half of 2025, Zepbound generated $5.69 billion in revenues, prompting Lilly to raise its full-year sales guidance to $60-$62 billion from its prior expectation of $58-$61 billion. By comparison, Wegovy recorded sales of $5.41 billion (DKK 36.9 billion) during the same period. Novo Nordisk revised its 2025 sales and operating profit outlook downward due to lower sales expectations from Wegovy as a result of intensified competition, including from compounded GLP-1 alternatives, and slower-than-anticipated market expansion, causing its stock price to plummet. However, Lilly's dominant position in the obesity market faced a setback last week following underwhelming efficacy results from the ATTAIN-1 study, the first of two pivotal phase III studies of its oral GLP-1 candidate, orforglipron. While the study met its primary and all key secondary endpoints across all three doses at 72 weeks, the 12.4% weight loss achieved with the highest 36 mg dose fell short of investor expectations, who had likely anticipated that orforglipron's efficacy would be more comparable to that of currently approved injectable GLP-1 treatments such as Zepbound and Wegovy. Investor sentiment was further dampened by the study's high patient discontinuation rates, stemming from both side effects and personal reasons, raising doubts about orforglipron's long-term utility in chronic obesity management. Given the strategic importance of orforglipron within Lilly's obesity pipeline, the perceived performance gap triggered an 18.6% decline in LLY shares over the past week. In response to LLY's setback, Novo Nordisk stock staged a modest recovery, suggesting a shift in market confidence toward its advancing oral obesity treatment programs. In the past week, NVO shares gained 4.7%. Oral Obesity Pills Emerge as the Next Battleground Eli Lilly's setback with its oral obesity pill has brought focus to oral treatment options for obesity. Oral pills have the potential to significantly reduce the treatment burden for obesity patients, which is expected to boost adherence over injections. NVO has already completed a regulatory filing seeking the approval of a 25 mg oral semaglutide for obesity, currently under review by the FDA. A decision from the regulatory body is expected by year-end. Potential approval would give Novo Nordisk a notable advantage as the sole manufacturer of a marketed oral obesity pill, positioning it to capture significant market share. Novo Nordisk is also developing a small-molecule oral CB1 inverse agonist, monlunabant, in a mid-stage study for obesity. The company is currently gearing up to advance Amycretin, an investigational unimolecular GLP-1 and amylin receptor agonist, for weight management into late-stage development. The phase III program on amycretin is planned to be initiated during the first quarter of 2026. Several other companies, like Viking Therapeutics VKTX, are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Recently, Viking Therapeutics started two late-stage studies evaluating the subcutaneous formulation of its investigational obesity drug, VK2735. A mid-stage study is currently ongoing, evaluating an oral version of this obesity drug, with a data readout expected later this year. LLY's Stock Price, Valuation and Estimates Shares of Eli Lilly have lost 19% so far this year compared with the industry's decline of 8.3%. The stock has also underperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below. LLY Stock Price Movement Image Source: Zacks Investment Research From a valuation standpoint, Lilly's stock is expensive. Going by the price/earnings ratio, the company's shares currently trade at 22.85 forward earnings, higher than 13.71 for the industry. However, the stock is trading much below its five-year mean of 34.54. LLY Stock Valuation Image Source: Zacks Investment Research Estimates for Eli Lilly's 2025 earnings have improved from $21.92 to $22.11 per share in the past 30 days, and estimates for 2026 earnings have declined from $30.84 to $30.74 over the same timeframe. LLY Estimate Movement Image Source: Zacks Investment Research Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
3 hours ago
- Business Wire
Science Fair Foundation of BC opens registration for Youth Innovation Showcase
VANCOUVER, British Columbia--(BUSINESS WIRE)--The Science Fair Foundation of BC (SFFBC) is excited to announce that registration is now open for the Youth Innovation Showcase (YIS), a virtual STEM competition with all-new dates. Youth across British Columbia and Yukon are invited to showcase their creativity and problem-solving skills by sharing science-based solutions to challenges in their life or community. Going into its seventh year, the Youth Innovation Showcase brings together passion, ingenuity and scientific creativity. Young people are constantly ideating how to solve some of the world's problems, and SFFBC aims to help illustrate that the youth of today will be the leaders of tomorrow's science and technology sector. Youth across British Columbia and Yukon are invited to showcase their creativity and problem-solving skills by sharing science-based solutions to challenges in their life or community. Share Whether a project is fully developed or just an idea, participants can compete individually or in teams of up to two people, and will be divided into two age categories: 12 to 15 years old and 16 to 19 years old, with each offering a $5,000 grand prize. Projects must be innovative and unique, as previous winning entries are not eligible for entry. For inspiration, participants can explore inspiration from past finalists and semi-finalists. "The Youth Innovation Showcase is back for its seventh year, and we couldn't be more excited to showcase the talent," said Sarah Prade, Executive Director of the Science Fair Foundation of BC. "Last year's applicants were truly inspiring, and we look forward to seeing the innovative ideas and unique skills this year's participants will bring to the table." The showcase has sponsorship and judging support from prominent organizations in BC's technology community, as well as returning alumni with a refreshed evaluation criteria. This year also marks the second edition of the YIS Visionary Award, celebrating young individuals who demonstrate entrepreneurial passion and excel in communication. Participants will showcase their ideas through compelling presentation materials, including a one-page report and a pitch video. The award will honour youth who are forward-thinking visionaries, identifying the future needs of their family, community, or society, and articulating how their innovation addresses those needs. Finalists will attend the Awards Show on January 28, 2026, where the grand prize winners will be announced and receive feedback from judges. The Awards Show has been pushed later this year to give students ample time over the winter break to prepare their Finalist submissions and get ready for their interviews. Please see below for the full list of key dates. For details on how to register, visit for more information and details on the YIS 2025 Workshop Series to help students get started. Important Dates Registration Opens – August 11, 2025 Registration Deadline – September 29, 2025 Semi-Finalists Announced – October 22, 2025 Semi-Finalist Interviews – November 18, 2025 Finalists Announced – December 1, 2025 Finalist Interviews – January 13, 2026 Awards Show – January 28, 2026 About Science Fair Foundation of BC The Science Fair Foundation of BC (SFFBC) is the largest volunteer science outreach network in the province, dedicated to fostering science and technology education by inspiring curiosity through the Science Fair program. Established in 1997, SFFBC supports Science Fairs across British Columbia and the Yukon by uniting over 1,500 educators, industry professionals, and volunteers as mentors, judges, and hosts. This collaboration empowers students to excel at regional, national, and international competitions, where Team BC has consistently achieved outstanding results. With 13 regional fairs in BC contributing to over 100 held annually across Canada, SFFBC plays a vital role in preparing the next generation for success in a knowledge-based economy.
